TPI 526

Drug Profile

TPI 526

Alternative Names: TPI-526

Latest Information Update: 24 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Teijin Pharma
  • Class Anti-inflammatories
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 19 Oct 2006 Phase-I clinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top